Approaches for targeting cancer stem cells drug resistance

References

• Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111. doi:10.1038/35102167
   PubMed Web of Science ®Google Scholar
• Ghisolfi L, Keates AC, Hu X, et al. Ionizing radiation induces stemness in cancer cells. PLoS One. 2012;7:e43628. doi:10.1371/journal.pone.0043628
   PubMed Web of Science ®Google Scholar
• Marcucci F, Rumio C, Lefoulon F. Anti-cancer stem-like cell compounds in clinical development – an overview and critical appraisal. Front Oncol. 2016;6:115. doi:10.3389/fonc.2016.00115
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–115. doi:10.1038/nature05384
   PubMed Web of Science ®Google Scholar
• Vermeulen L, de Sousa e Melo F, Richel DJ, et al. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012;13:e83–e89. doi:10.1016/S1470-2045(11)70257-1
   PubMed Web of Science ®Google Scholar
• Visvader JE. Cells of origin in cancer. Nature. 2011;469:314–322. doi:10.1038/nature09781
   PubMed Web of Science ®Google Scholar
• Marcucci F, Bellone M, Caserta CA, et al. Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads. Int J Cancer. 2014;135:1265–1276. doi:10.1002/ijc.v135.6
   PubMed Web of Science ®Google Scholar
• Vaz AP, Deb S, Rachagani S, et al. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:3317–3331. doi:10.18632/oncotarget.6580
   PubMed Web of Science ®Google Scholar
• Wang Y, Cardenas H, Fang F, et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 2014;74:4922–4936. doi:10.1158/0008-5472.CAN-14-1022
   PubMed Web of Science ®Google Scholar
• Catanzaro JM, Sheshadri N, Pan JA, et al. Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun. 2014;5:3729. doi:10.1038/ncomms5972
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715. doi:10.1016/j.cell.2008.03.027
   PubMed Web of Science ®Google Scholar
• Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–273. doi:10.1038/nrc2620
   PubMed Web of Science ®Google Scholar
• Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells – what challenges do they pose? Nat Rev Drug Discov. 2014;13:497–512. doi:10.1038/nrd4253
   PubMed Web of Science ®Google Scholar
• Shackleton M. Normal stem cells and cancer stem cells: similar and different. Semin Cancer Biol. 2010;20:85–92. doi:10.1016/j.semcancer.2010.04.002
   PubMed Web of Science ®Google Scholar
• Mitra A, Mishra L, Li S. EMT, CTCs, CSCs in tumor relapse and drug-resistance. Oncotarget. 2015;6:10697–10711. doi:10.18632/oncotarget
   PubMed Web of Science ®Google Scholar
• Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7:1028–1034. doi:10.1038/nm0901-1028
   PubMed Web of Science ®Google Scholar
• Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.
   PubMed Web of Science ®Google Scholar
• Bates RC, Edwards NS, Burns GF, et al. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 2001;61:5275–5283.
   PubMed Web of Science ®Google Scholar
• Sarvi S, Mackinnon AC, Avlonitis N, et al. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014;74:1554–1565. doi:10.1158/0008-5472.CAN-13-1541
   PubMed Web of Science ®Google Scholar
• Fernando J, Malfettone A, Cepeda EB, et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer. 2015;136:E161–E172. doi:10.1002/ijc.29097
   Google Scholar
• Hashimoto N, Tsunedomi R, Yoshimura K, et al. Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer. 2014;14:722. doi:10.1186/1471-2407-14-722
   PubMed Web of Science ®Google Scholar
• Li Y, Ma J, Qian X, et al. Regulation of EMT by Notch signaling pathway in tumor progression. Curr Cancer Drug Targets. 2013;13:957–962. doi:10.2174/15680096113136660101
   PubMed Web of Science ®Google Scholar
• Saxena M, Stephens M, Pathak H, et al. Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2:e179. doi:10.1038/cddis.2011.82
   PubMed Web of Science ®Google Scholar
• Liu WH, Chen MT, Wang ML, et al. Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells. Oncotarget. 2015;6:1750–1768. doi:10.18632/oncotarget.2737
   PubMed Web of Science ®Google Scholar
• Kong Y, Peng Y, Liu Y, et al. Twist1 and Snail link Hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters. Stem Cells. 2015;33:1063–1074. doi:10.1002/stem.1955
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Kong D, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;15(69):2400–2407. doi:10.1158/0008-5472.CAN-08-4312
   Web of Science ®Google Scholar
• Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527:525–530. doi:10.1038/nature15724
   PubMed Web of Science ®Google Scholar
• Chang L, Graham PH, Hao J, et al. Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013;4:e875. doi:10.1038/cddis.2013.407
   PubMed Web of Science ®Google Scholar
• Garg M. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer. Expert Opin Ther Targets. 2015;19:285–297. doi:10.1517/14728222.2014.975794
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zheng L, Huang J, et al. MiR-124 radiosensitizes human colorectal cancer cells by targeting PRRX1. PLoS One. 2014;9:e93917. doi:10.1371/journal.pone.0093917
   PubMedGoogle Scholar
• Ma J, Fang B, Zeng F, et al. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Oncotarget. 2015;6:1740–1749. doi:10.18632/oncotarget.2714
   PubMed Web of Science ®Google Scholar
• Bai W, Ye X, Zhang M, et al. MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer. 2014;135:1356–1368. doi:10.1002/ijc.28782
   PubMed Web of Science ®Google Scholar
• Meidhof S, Brabletz S, Lehmann W, et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med. 2015;7:831–847. doi:10.15252/emmm.201404967
   PubMed Web of Science ®Google Scholar
• Padua Alves C, Fonseca AS, Muys BR, et al. Brief report: the lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines. Stem Cells. 2013;31:2827–2832. doi:10.1002/stem.1547
   PubMed Web of Science ®Google Scholar
• Wu L, Murat P, Matak-Vinkovic D, et al. Binding interactions between long noncoding RNA HOTAIR and PRC2 proteins. Biochemistry. 2013;52:9519–9527. doi:10.1021/bi401085h
   PubMed Web of Science ®Google Scholar
• Peitzsch C, Cojoc M, Hein L, et al. An epigenetic reprogramming strategy to re-sensitize radioresistant prostate cancer cells. Cancer Res. 2016;76:2637–2651. doi:10.1158/0008-5472.CAN-15-2116
   PubMed Web of Science ®Google Scholar
• Codony-Servat J, Rosell R. Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res. 2015;4:689–703. doi:10.3978/j.issn.2218-6751.2015.12.11
   PubMed Web of Science ®Google Scholar
• Bandhavkar S. Cancer stem cells: a metastasizing menace!. Cancer Med. 2016;5:649–655. doi:10.1002/cam4.629
   PubMed Web of Science ®Google Scholar
• Brunton VG, Frame MC. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol. 2008;8:427–432. doi:10.1016/j.coph.2008.06.012
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Richter J, Barbany G, et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 2013;27:1520–1526. doi:10.1038/leu.2013.19
   PubMed Web of Science ®Google Scholar
• Clinical Trials.Gov. ID NCT02372227. Available from: www.clinicaltrials.org
   Google Scholar
• Jones SF, Siu LL, Bendell JC, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33:1100–1107. doi:10.1007/s10637-015-0282-y
   PubMed Web of Science ®Google Scholar
• Shapiro IM, Kolev VN, Vidal CM, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6:237ra68. doi:10.1126/scitranslmed.3008639
   PubMed Web of Science ®Google Scholar
• Lee BY, Hochgräfe F, Lin HM, et al. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol Cancer Ther. 2014;13:190–201. doi:10.1158/1535-7163.MCT-13-0225-T
   PubMed Web of Science ®Google Scholar
• Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7–24. doi:10.1038/nrc3860
   PubMed Web of Science ®Google Scholar
• Kolev VN, Wright QG, Vidal CM, et al. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Res. 2015;75:446–455. doi:10.1158/0008-5472.CAN-14-3569
   PubMed Web of Science ®Google Scholar
• Chen J, Shao R, Li F, et al. PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. Clin Exp Pharmacol Physiol. 2015;42:1317–1326. doi:10.1111/1440-1681.12493
   PubMed Web of Science ®Google Scholar
• Samatar AA, Pulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13:928–942. doi:10.1038/nrd4281
   PubMed Web of Science ®Google Scholar
• Balko JM, Schwarz LJ, Bhola NE, et al. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 2013;73:6346–6358. doi:10.1158/0008-5472.CAN-13-1385
   PubMed Web of Science ®Google Scholar
• Judd NP, Winkler AE, Murillo-Sauca O, et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012;72:365–374. doi:10.1158/0008-5472.CAN-11-1831
   PubMed Web of Science ®Google Scholar
• Sette G, Salvati V, Memeo L, et al. EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS One. 2012;7:e46891. doi:10.1371/journal.pone.0046891
   Web of Science ®Google Scholar
• Kim G, McKee AE, Ning YM, et al. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014;20:4994–5000. doi:10.1158/1078-0432.CCR-13-3045
   PubMed Web of Science ®Google Scholar
• Bowman T, Broome MA, Sinibaldi D, et al. STAT3–mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A. 2001;98:7319–7324. doi:10.1073/pnas.131568898
   PubMed Web of Science ®Google Scholar
• Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736–746. doi:10.1038/nrc3818
   PubMed Web of Science ®Google Scholar
• Li Y, Rogoff HA, Keates S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015;112:1839–1844. doi:10.1073/pnas.1424171112
   PubMed Web of Science ®Google Scholar
• Senger MR, Fraga CA, Dantas RF, et al. Filtering promiscuous compounds in early drug discovery: is it a good idea? Drug Discov Today. 2016;21:868–872. doi:10.1016/j.drudis.2016.02.004
   PubMed Web of Science ®Google Scholar
• Santaliz-Ruiz IV, Luis E, Xie X, et al. Emerging role of Nanog in tumorigenesis and cancer stem cells. Int J Cancer. 2014;135:2741–2748. doi:10.1002/ijc.28690
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhu H, Shan H, et al. Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Cancer Lett. 2013;340:113–123. doi:10.1016/j.canlet.2013.06.021
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507–7511. doi:10.1158/0008-5472.CAN-08-3660
   PubMed Web of Science ®Google Scholar
• Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563–575. doi:10.1038/nrc2676
   PubMed Web of Science ®Google Scholar
• Janzer A, German NJ, Gonzalez-Herrera KN, et al. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci U S A. 2014;111:10574–10579. doi:10.1073/pnas.1409844111
   PubMed Web of Science ®Google Scholar
• Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, et al. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle. 2010;9:4461–4468. doi:10.4161/cc.9.22.14048
   PubMed Web of Science ®Google Scholar
• Li L, Han R, Xiao H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 2014;20:2714–2726. doi:10.1158/1078-0432.CCR-13-3045
   PubMed Web of Science ®Google Scholar
• Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13:513–532. doi:10.1038/nrd4233
   PubMed Web of Science ®Google Scholar
• Zhang K-Z, Zhang Q-B, Zhang Q-B, et al. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. J Hematol Oncol. 2014;7:28. doi:10.1186/1756-8722-7-28
   PubMed Web of Science ®Google Scholar
• De Menna M, D’Amato V, Ferraro A, et al. Wnt4 inhibits cell motility induced by oncogenic Ras. Oncogene. 2013;32:4110–4119. doi:10.1038/onc.2012.419
   PubMed Web of Science ®Google Scholar
• Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.
   PubMed Web of Science ®Google Scholar
• Eaves CJ, Humphries RK. Acute myeloid leukemia and the Wnt pathway. N Engl J Med. 2010;362:2326–2327. doi:10.1056/NEJMcibr1003522
   PubMed Web of Science ®Google Scholar
• Monteiro J, Gaspar C, Richer W, et al. Cancer stemness in Wnt-driven mammary tumorigenesis. Carcinogenesis. 2014;35:2–13. doi:10.1093/carcin/bgu107
   PubMed Web of Science ®Google Scholar
• de Sousa e Melo F, Vermeulen L. Wnt signaling in cancer stem cell biology. Cancers. 2016;8. pii:E60. doi:10.3390/cancers8070060
   PubMed Web of Science ®Google Scholar
• White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142:219–232. doi:10.1053/j.gastro.2011.12.001
   PubMed Web of Science ®Google Scholar
• Yoon JK, Lee JS. Cellular signaling and biological functions of R-spondins. Cell Sign. 2012;24:369–377. doi:10.1016/j.cellsig.2011.09.023
   PubMed Web of Science ®Google Scholar
• Storm EE, Durinck S, de Sousa e Melo F, et al. Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature. 2016;529:97–100. doi:10.1038/nature16466
   PubMed Web of Science ®Google Scholar
• Gurney A, Axelrod F, Bond CJ, et al. Wnt pathway inhibition via the targeting of frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012;109:11717–11722. doi:10.1073/pnas.1120068109
   PubMed Web of Science ®Google Scholar
• Le PN, McDermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther. 2015;146:1–11. doi:10.1016/j.pharmthera.2014.08.005
   PubMed Web of Science ®Google Scholar
• Jang G-B, Hong I-S, Kim R-J, et al. Wnt/β-catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells. Cancer Res. 2015;75:1691–1702. doi:10.1158/0008-5472.CAN-14-3569
   PubMed Web of Science ®Google Scholar
• Leong KJ, Niessen K, Kulic I, et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through slug-induced repression of E-cadherin. J Exp Med. 2007;204:2935–2948. doi:10.1084/jem.20071082
   PubMed Web of Science ®Google Scholar
• Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling – are we there yet? Nat Rev Drug Discov. 2014;13:357–378. doi:10.1038/nrd4252
   PubMed Web of Science ®Google Scholar
• Cohen B, Shimizu M, Izrailit J, et al. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res Treat. 2010;123:113–124. doi:10.1007/s10549-009-0621-9
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22:373–388. doi:10.1016/j.ccr.2012.07.016
   PubMed Web of Science ®Google Scholar
• Huynh C, Poliseno L, Segura MF, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One. 2011;6:e25264. doi:10.1371/journal.pone.0025264
   PubMed Web of Science ®Google Scholar
• Smith DC, Eisenberg PD, Manikhas G, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014;20:6295–6303. doi:10.1158/1078-0432.CCR-14-1373
   PubMed Web of Science ®Google Scholar
• Yen WC, Fischer MM, Axelrod F, et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015;21:2084–2095. doi:10.1158/1078-0432.CCR-14-2808
   PubMed Web of Science ®Google Scholar
• Diaz-Padilla I, Wilson MK, Clarke BA, et al. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol. 2015;137:216–222. doi:10.1016/j.ygyno.2015.03.005
   PubMed Web of Science ®Google Scholar
• Teglund and Toftgård. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta. 2010;1805:181–208.
   PubMed Web of Science ®Google Scholar
• Yue D, Li H, Che J, et al. Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J Exp Clin Cancer Res. 2014;33:34. doi:10.1186/1756-9966-33-34
   PubMed Web of Science ®Google Scholar
• Chari NS, McDonnell TJ. The sonic hedgehog signaling network in development and neoplasia. Adv Anat Pathol. 2007;14:344–352. doi:10.1097/PAP.0b013e3180ca8a1d
   PubMed Web of Science ®Google Scholar
• D’Amato C, Rosa R, Marciano R, et al. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014;111:1168–1179. doi:10.1038/bjc.2014.421
   PubMed Web of Science ®Google Scholar
• Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature. 2000;406:1005–1009. doi:10.1038/35020557
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–2179. doi:10.1056/NEJMoa1113713
   PubMed Web of Science ®Google Scholar
• Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16:716–728. doi:10.1016/S1470-2045(15)70100-2
   PubMed Web of Science ®Google Scholar
• Singh BN, Fu J, Srivastava RK, et al. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One. 2011;6:e27306. doi:10.1371/journal.pone.0027306
   PubMed Web of Science ®Google Scholar
• Kim EJ, Sahai V, Abel EV, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014;20:5937–5945. doi:10.1158/1078-0432.CCR-13-3045
   PubMed Web of Science ®Google Scholar
• Santibañez JF, Quintanilla M, Bernabeu C. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci. 2011;121:233–251. doi:10.1042/CS20110086
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274–284. doi:10.1038/nrc2622
   PubMed Web of Science ®Google Scholar
• Ohnuki H, Jiang K, Wang D, et al. Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-β signaling to drive malignant progression. Cancer Res. 2014;74:2038–2049. doi:10.1158/0008-5472.CAN-13-3514
   PubMed Web of Science ®Google Scholar
• Morris JC, Tan AR, Olencki TE, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One. 2014;9:e90353.
   PubMed Web of Science ®Google Scholar
• Park SY, Kim MJ, Park SA, et al. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells. Oncotarget. 2015;6:37526–37543.
   PubMed Web of Science ®Google Scholar
• Bhola NE, Balko JM, Dugger TC, et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123:1348–1358. doi:10.1172/JCI65416
   PubMed Web of Science ®Google Scholar
• Shiota M, Zardan A, Takeuchi A, et al. Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res. 2012;72:5261–5272. doi:10.1158/0008-5472.CAN-12-0254
   PubMed Web of Science ®Google Scholar
• Zhang S, Cui B, Lai H, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem- cell therapy. Proc Natl Acad Sci U S A. 2014;111:17266–17271. doi:10.1073/pnas.1419599111
   PubMed Web of Science ®Google Scholar
• Cui B, Zhang S, Chen L, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013;73:3649–3660.
   PubMed Web of Science ®Google Scholar
• Hirohashi Y, Torigoe T, Tsukahara T, et al. Immune responses to human cancer stem-like cells/cancer-initiating cells. Cancer Sci. 2016;107:12–17.
   PubMed Web of Science ®Google Scholar
• Segal NH, Parsons DW, Peggs KS, et al. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008;68:889–892. doi:10.1158/0008-5472.CAN-07-3095
   PubMed Web of Science ®Google Scholar
• Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res. 2008;68:2419–2426.
   PubMed Web of Science ®Google Scholar
• Gedye C, Quirk J, Browning J, et al. Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother. 2009;58:1635–1646. doi:10.1007/s00262-009-0672-0
   PubMed Web of Science ®Google Scholar
• Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol. 2004;82:249–293. doi:10.1016/S0065-2776(04)82006-6
   PubMed Web of Science ®Google Scholar
• Barve M, Bender J, Senzer N, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008;26:4418–4425. doi:10.1200/JCO.2008.16.6462
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol. 2007;25:7554.
   Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi:10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. doi:10.1056/NEJMoa1011205
   PubMed Web of Science ®Google Scholar
• Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945–950. doi:10.1111/cas.12695
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030. doi:10.1200/JCO.2013.54.6911
   PubMed Web of Science ®Google Scholar
• Sanborn RE, Sharfman WH, Segal NH, et al. A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. J Clin Oncol. 2013;31:abstr TPS3110. doi:10.1200/JCO.2013.49.0219
   Google Scholar
• Iversen TZ, Engell-Noerregaard L, Ellebaek E, et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res. 2014;20:221–232. doi:10.1158/1078-0432.CCR-13-1560
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24:4721–4730. doi:10.1200/JCO.2005.05.5335
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. doi:10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218. doi:10.1038/nature12213
   PubMed Web of Science ®Google Scholar
• Krawczyk N, Meier-Stiegen F, Banys M, et al. Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients. Biomed Res Int. 2014;2014:415721. doi:10.1155/2014/415721
   PubMed Web of Science ®Google Scholar